PDCD1 and gastric cancer: In addition, Sakaguchis’ group reported, in advanced gastric cancer patients who do not respond to anti-PD-1 mAb, that the frequency of proliferating (Ki67+) effector TA-Tregs is increased in the TME compared to patients responding to treatment.